☰

Yelena Mirochnik, Ph.D. - Publications

Affiliations: 
2003 Rush University, Chicago, IL, United States 
Area:
Oncology, Cell Biology, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

25 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2012 Mirochnik Y, Veliceasa D, Williams L, Maxwell K, Yemelyanov A, Budunova I, Volpert OV. Androgen receptor drives cellular senescence. Plos One. 7: e31052. PMID 22403609 DOI: 10.1371/Journal.Pone.0031052  0.486
2011 Kai L, Wang J, Ivanovic M, Chung YT, Laskin WB, Schulze-Hoepfner F, Mirochnik Y, Satcher RL, Levenson AS. Targeting prostate cancer angiogenesis through metastasis-associated protein 1 (MTA1). The Prostate. 71: 268-80. PMID 20717904 DOI: 10.1002/Pros.21240  0.457
2009 Mirochnik Y, Aurora A, Schulze-Hoepfner FT, Deabes A, Shifrin V, Beckmann R, Polsky C, Volpert OV. Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1655-63. PMID 19223494 DOI: 10.1158/1078-0432.Ccr-08-2113  0.424
2009 Mirochnik Y, Kwiatek A, Volpert OV. Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments. Current Drug Targets. 9: 851-62. PMID 18855619 DOI: 10.2174/138945008785909347  0.302
2009 Maxwell KM, Mirochnik Y, Williams LV, Volpert OV. IDENTIFICATION OF AR TARGETS CRITICAL FOR TUMOR SENESCENCE Journal of Urology. 181: 94-94. DOI: 10.1016/S0022-5347(09)60267-6  0.365
2008 Mirochnik Y, Maxwell KM, Deabes A, Veliceasa D, Williams LV, Schulze-Hoepfner FT, Volpert OV. IDENTIFYING MECHANISMS OF SENESCENCE IN PROSTATE CANCER Journal of Urology. 179: 102-102. DOI: 10.1016/S0022-5347(08)60297-9  0.464
2007 Mirochnik Y, Rubenstein M, Guinan P. Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles Journal of Drug Targeting. 15: 342-350. PMID 17541843 DOI: 10.1080/10611860701350099  0.665
2007 Nelius T, Filleur S, Yemelyanov A, Budunova I, Shroff E, Mirochnik Y, Aurora A, Veliceasa D, Xiao W, Wang Z, Volpert OV. Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo. International Journal of Cancer. 121: 999-1008. PMID 17487836 DOI: 10.1002/Ijc.22802  0.593
2007 Nelius T, Filleur S, Shroff E, Mirochnik Y, Valiceasa D, De Riese W, Volpert O. 93 THE PRO-APOPTOTIC AND ANTI-ANGIOGENIC EFFECTS OF ANDROGEN IN THE IN VIVO MODEL OF PROSTATE CANCER European Urology Supplements. 6: 46. DOI: 10.1016/S1569-9056(07)60092-X  0.412
2007 Nelius T, Filleur S, Shroff E, Mirochnik Y, de Riese W, Volpert O. 269: The Pro-Apoptotic and Anti-Angiogenic Effects of Androgen in the in vivo Model of Prostate Cancer Journal of Urology. 177: 90-90. DOI: 10.1016/S1569-9056(07)60092-X  0.412
2005 Filleur S, Volz K, Nelius T, Mirochnik Y, Huang H, Zaichuk TA, Aymerich MS, Becerra SP, Yap R, Veliceasa D, Shroff EH, Volpert OV. Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer Cancer Research. 65: 5144-5152. PMID 15958558 DOI: 10.1158/0008-5472.Can-04-3744  0.451
2004 Mirochnik Y, Rubenstein M, Guinan P. Two constructed antibody-derived delivery vehicles for targeting oligodeoxynucleotides to prostate tumors expressing prostate specific antigen Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents. 11: 161-167. PMID 15204635 DOI: 10.1080/10717540490433859  0.667
2003 Rubenstein M, Slobodskoy L, Mirochnik Y, Guinan P. Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol Medical Oncology. 20: 29-35. PMID 12665682 DOI: 10.1385/Mo:20:1:29  0.691
2002 Rubenstein M, Slobodskoy L, Mirochnik Y, Guinan P. Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-α or EGFR in the treatment of prostate cancer cell lines Methods and Findings in Experimental and Clinical Pharmacology. 24: 649-652. PMID 12616956 DOI: 10.1358/Mf.2002.24.10.802313  0.682
2001 Rubenstein M, Mirochnik Y, Slobodskoy L, Guinan P. Biotinylation of antisense oligonucleotides does not alter lipofectin enhanced cellular uptake in prostate cancer cell lines Methods and Findings in Experimental and Clinical Pharmacology. 23: 487-490. PMID 11876021  0.649
2001 Rubenstein M, Glick R, Lichtor T, Mirochnik Y, Chou P, Guinan P. Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-α and the epidermal growth factor receptor Medical Oncology. 18: 121-130. PMID 11778757 DOI: 10.1385/Mo:18:2:121  0.647
1999 Rubenstein M, Shaw M, Mirochnik Y, Slobodskoy L, Glick R, Lichtor T, Chou P, Guinan P. In vivo establishment of T98G human glioblastoma Methods and Findings in Experimental and Clinical Pharmacology. 21: 391-393. PMID 10445230 DOI: 10.1358/Mf.1999.21.6.541918  0.629
1998 Rubenstein M, Mirochnik Y, Chou P, Guinan P. Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides Methods and Findings in Experimental and Clinical Pharmacology. 20: 825-831. PMID 10091218 DOI: 10.1358/Mf.1998.20.10.487534  0.71
1998 Guinan P, Shaw M, Mirochnik Y, Slobodskoy L, Ray V, Rubenstein M. Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model Methods and Findings in Experimental and Clinical Pharmacology. 20: 739-742. PMID 10022026  0.659
1998 Shaw M, Ratanawong S, Chou P, Ray V, Mirochnik Y, Slobodskoy L, Rubenstein M, Guinan P. Paclitaxel, bropirimine and linomide: Effect on growth inhibition in a murine prostate cancer model by different growth regulatory mechanisms Methods and Findings in Experimental and Clinical Pharmacology. 20: 111-114. PMID 9604852 DOI: 10.1358/Mf.1998.20.2.481838  0.694
1998 Uzoaru I, Rubenstein M, Mirochnik Y, Slobodskoy L, Shaw M, Guinan P. An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer Journal of Surgical Oncology. 67: 33-37. PMID 9457254 DOI: 10.1002/(Sici)1096-9098(199801)67:1<33::Aid-Jso7>3.0.Co;2-N  0.572
1997 Rubenstein M, Mirochnik Y, Ray V, Guinan P. Lack of toxicity associated with the systemic administration of antisense oligonucleotides for treatment of rats bearing LNCaP prostate tumors. Medical Oncology (Northwood, London, England). 14: 131-6. PMID 9468034 DOI: 10.1007/Bf02989639  0.685
1997 Rubenstein M, Chou P, Mirochnik Y, Guinan P. Enhanced expression of bcl-2 following antisense oligonucleotide mediated growth factor deprivation. Medical Oncology (Northwood, London, England). 14: 23-9. PMID 9232607 DOI: 10.1007/Bf02990941  0.689
1996 Lievano G, Mirochnik Y, Rubenstein M, Shaw M, Guinan P. Antitumor effect of CPT-11, a new derivative of camptothecin, against human prostate cancer (PC-3) in vitro and prostate rat tumor (AT-3) in vivo. Methods and Findings in Experimental and Clinical Pharmacology. 18: 659-62. PMID 9121221  0.692
1996 Rubenstein M, Mirochnik Y, Chou P, Guinan P. Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice. Journal of Surgical Oncology. 62: 194-200. PMID 8667627 DOI: 10.1002/(Sici)1096-9098(199607)62:3<194::Aid-Jso9>3.0.Co;2-2  0.632
Show low-probability matches.